Peer Review History
| Original SubmissionFebruary 27, 2021 |
|---|
|
PONE-D-21-06574 Psiadin and Plectranthone selectively inhibit colorectal carcinoma cells proliferation via modulating cyclins signaling and apoptotic pathways PLOS ONE Dear Dr. Khaled Y Orabi, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript within 3 weeks time. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Mahmood ur Rahman Ansari, Ph.D Academic Editor PLOS ONE Additional Editor Comments: 1. The authors are advised to address the comments raised by the reviewers. Especially, reviewer 1 has made significant improvements in English language. Please see the attached edited copy of the article which Reviewer 1 has attached. Reviewers 2 and 3 gave valuable suggestions to improve the manuscript. Please provide pint-wise reply to each of the comment and mention changes in cover letter where needed. 2. The authors are required to submit original pictures of Gel Electrophoresis given in Figure-5 Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels. In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions. Reviewers' comments: Reviewer #1: I am happy to see the elaboration of manuscript. But, it has some scientific issues in the current version, and I have highlighted issues here in the attached MS file. Therefore, the present draft should be revised accordingly. Moreover, following reference could be cited; https://doi.org/10.1016/j.toxicon.2020.10.012 Reviewer #2: Orabi et al., has tested the effect of various terpenes as anti-cancerous natural products. Out of three compounds tested, Psiadins were found to have promising anti cancerous effect than PC2 as measured by cytotoxicity, mitochondrial membrane potential, and ROS production. Authors have also hinted upon the involvement of NFkb downstream to the effect of selected terpenes. However, a detailed mechanism remains to be answered. Overall the study tries to address relevant translational question however looks preliminary. Some questions to address are mentioned below: 1. Why colorectal cancer cell lines are selected? Any history of specific effect of terpenes vs. colorectal cancer? 2. Are the compounds added only once and followed for observation or replenished after every 24 hrs? This is important considering varying half-life of various compounds. 3. The quality of images are not up to the mark, too difficult to follow the details. Image 1d, 3b, 4c & some blots looks similar to the authors preprint describing effect of terpenes in Hepato carcinoma cells. This also reflects that terpenes have broad anti proliferative activity against range of cell types (as reported previously in literature) . 4. Please properly rearrange the blots with labeling. 5. What is the logic of culturing cells in a non-CO2 incubator? Do authors mean hypoxic conditions to induce stress? 6. What is the IC50 of compounds? How are the doses selected to test for toxicity? 7. Why no great difference was observed on treatment of PC2 with 200 and 400 uM (Fig 1d), whereas in Fig 4a, b significant inhibition (TF activity) was observed on treatment of 400 uM of PC2. 8. Result headings should describe the major results discussed. For eg measuring ROS and protein expression are not appropriate. 9. There should be a clear demarcation of results and discussion to increase the readability of the work. Reviewer #3: Overall, this is a concise, clear, well planned and well executed study. The manuscript is well-written. The study focused on anticancer potential of three scarce terpenes, psiadin, plectranthone and saudinolide. Their anticancer activity was tested on two human colorectal carcinoma cell lines, CCL233 and CCL235. The presentation of data is clear and concise in text and figures. Results have been explained comprehensively and discussed critically to reach conclusions. Bibliography contains complete, accurate and up-to-date list of references with cautious care given to research ethics, including plagiarism and proper citation.This is a good quality manuscript but some MAJOR REVISIONS are required before it is accepted for publication. PLease also include synergism (if any) between the terpenes tested in this study with standard drug. ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.
|
| Revision 1 |
|
Psiadin and Plectranthone selectively inhibit colorectal carcinoma cells proliferation via modulating cyclins signaling and apoptotic pathways PONE-D-21-06574R1 Dear Dr. Khaled Y Orabi, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Mahmood ur Rahman Ansari, Ph.D Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: |
| Formally Accepted |
|
PONE-D-21-06574R1 Psiadin and Plectranthone selectively inhibit colorectal carcinoma cells proliferation via modulating cyclins signaling and apoptotic pathways Dear Dr. Orabi: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Mahmood ur Rahman Ansari Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .